September 13, 2018 / 6:41 PM / 2 months ago

FDA approves AstraZeneca's drug for rare form of blood cancer

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

(Reuters) - The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc’s treatment for hairy cell leukemia, a slow-growing type of blood cancer.

The treatment, marketed as Lumoxiti, was approved for treating a stubborn form of the disease or a relapse in patients who have received at least two prior therapies, the FDA here said.

Lumoxiti includes a boxed warning advising health care professionals and patients about the risk of developing capillary leak syndrome, a condition in which fluid and proteins leak out of tiny blood vessels.

The warning also notes the risk of hemolytic uremic syndrome, a condition caused by the abnormal destruction of red blood cells.

Hairy cell leukemia is a rare form of blood cancer in which the bone marrow makes too many B cells, a type of white blood cell that fights infection.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D'Silva

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below